CLAIMS

1. Annexin A5 protein for use in the prophylaxis or the treatment of osteoarthritis in one or more joints, in a subject;

wherein the or each joint is selected from the list consisting of: a synovial joint; an amphiarthrosis joint; and a synarthrosis joint.

2. The Annexin A5 protein for the use according to Claim 1, wherein the Annexin A5 protein is administered to the or each joint.

3. Annexin A5 protein for use in the prophylaxis or the treatment of osteoarthritis in one or more joints, in a subject;

wherein the Annexin A5 protein is administered to the or each joint.

4. The Annexin A5 protein for the use according to Claim 3, wherein the or each joint is selected from the list consisting of: a synovial joint; an amphiarthrosis joint; and a synarthrosis joint.

5. The Annexin A5 protein for the use according to any of the preceding claims, wherein the osteoarthritis is primary osteoarthritis or secondary osteoarthritis.

6. The Annexin A5 protein for the use according to Claim 5, wherein the primary osteoarthritis is generalised nodal osteoarthritis or erosive osteoarthritis.

7. Annexin A5 protein for use in the prophylaxis or the treatment of erosive osteoarthritis in one or more joints, in a subject;

optionally, wherein the Annexin A5 protein is administered to the or each joint; and/or

optionally, wherein the or each joint is selected from the list consisting of: a synovial joint; an amphiarthrosis joint; and a synarthrosis joint.

8. The Annexin A5 protein for the use in treating osteoarthritis in the subject according to any of the preceding claims, wherein the subject has osteoarthritis in the or each joint.

9. The Annexin A5 protein for the use according to any of the preceding claims, wherein the subject has been diagnosed with osteoarthritis;

optionally, wherein the diagnosis of osteoarthritis is in the or each joint to be treated.

10. The Annexin A5 protein for the use according to any of Claims 1, 2 or 4-9, wherein the synovial joint is one or more synovial joint selected from the list consisting of: a plane joint (for example, a costovertebral joint, a facet joint, a midcarpal joint, a carpometacarpal finger joint, an intermetacarpal joint, a sacroiliac joint, a zygapophyseal joint, a sternocostal joint, subtalar joint (or talocalcaneal joint), or an acromioclavicular joint); a ball and socket joint (for example, a tibiotarsal joint, a tibiofibular joint, a shoulder joint, a talocalcaneonavicular joint, or a hip joint); a hinge joint (for example, an ankle joint, an elbow joint, a temporomandibular joint, an interphalangeal joint, a stifle joint, or a knee joint); a pivot joint (for example, an atlantoaxial joint, an atlanto-axial joint, a proximal radioulnar joint, a hock joint, a tarsal joint, a talocalcaneonavicular joint, a calcaneocuboid joint, or a distal radioulnar joint); a condyloid joint (for example, an atlanto-occipital joint, a radiocarpal joint, a metatarsophalangeal joint, a wrist joint, an intercarpal joint, a radiocarpal joint, or a metacarpophalangeal joint); and a saddle joint (for example, a carpometacarpal thumb joint, a calcaneocuboid joint, or a sternoclavicular joint).

11. The Annexin A5 protein for the use according to any of the preceding claims, wherein the subject is not a juvenile and/or is a subject that has completed physical growth.

12. The Annexin A5 protein for the use according to any of the preceding claims, wherein the subject is a mammalian subject, such as a human, an equine (including a horse), a bovine, a camel, a pig, a llama, an alpaca, a sheep, a goat, a canine, a feline, a rabbit, or a rodent.

13. The Annexin A5 protein for the use according to Claim 12, wherein the subject is a human.

14. The Annexin A5 protein for the use according to Claim 13, wherein the subject is 45 or more years of age.

15. The Annexin A5 protein for the use according to Claim 12, wherein the subject is a horse.

16. The Annexin A5 protein for the use according to Claim 15, wherein the subject is 5 or more years of age.

17. The Annexin A5 protein for the use according to any of the preceding claims, wherein the Annexin A5 protein is administered at a concentration of at least 1 µg/ml.

18. The Annexin A5 protein for the use according to any of the preceding claims, wherein the Annexin A5 protein is:

a) a protein comprising, consisting essentially of, or consisting of the sequence of human Annexin A5 (optionally, a protein consisting of the sequence of SEQ ID NO:1, either with or without the N-terminal methionine);

b) a mammalian orthologue of human Annexin A5;

c) an allelic or genetic variant of a) or b);

d) a functional analogue or variant of Annexin which is a protein which is more than 50%, 60%, 70%, 75%, such as more than 80%, 85%, more than 90%, or even more preferably more than 95% or 99% identical to human Annexin A5, SEQ ID NO:1 either with, or without, the N-terminal methionine;

e) a biologically active fragment of any of a), b), c), or d);

f) a monomer consisting of, a dimer comprising or consisting of, or a fusion protein comprising, any of a), b), c), d) or e); and

g) a PEGylated variant of any of a), b), c), d), e) or f).

19. The Annexin A5 protein for the use according to any of the preceding claims, wherein the Annexin A5 protein is formulated in a composition, such as a pharmaceutically acceptable composition or a veterinarially acceptable composition.

20. The Annexin A5 protein for the use according to any of the preceding claims, wherein the Annexin A5 protein or composition is administered into the or each joint at a volume of 1ml or more;

optionally, wherein the Annexin A5 protein or composition is administered into the or each joint at a volume of 10ml or less.

21. The Annexin A5 protein for the use according to any of the preceding claims, wherein the subject is treated with Annexin A5 protein or composition separately, simultaneously or sequentially with one or more additional treatments, selected from one or more of: lifestyle changes; medication; and surgery.

22. Annexin A5 protein or composition for use, or use, or method as substantially described herein, with reference to the description and/or figures.